镰状细胞视网膜病变严重程度相关的临床与眼科因素
该回顾性队列研究纳入296例同时就诊于镰状细胞病专科门诊和视网膜门诊的患者,分析镰状细胞视网膜病变(SCR)严重程度与临床、实验室及治疗因素的关系。多因素分析显示,镰状细胞贫血基因型患者中年龄较大和男性与增殖性镰状细胞视网膜病变(PSR)相关;基因变异型患者中视觉症状与PSR相关。激光光凝和玻璃体切除术与年龄较大、视觉症状、较高血红蛋白水平及未接受慢性输血相关。
要点
- 镰状细胞贫血基因型患者中,年龄较大和男性与增殖性视网膜病变相关。
- 基因变异型患者中,视觉症状与增殖性视网膜病变相关。
- 慢性输血治疗可能减少需视网膜激光或玻璃体手术的风险。
核心结论
- 镰状细胞贫血基因型患者中年龄较大和男性与增殖性镰状细胞视网膜病变相关。
- 基因变异型患者中视觉症状与增殖性镰状细胞视网膜病变相关。
- 慢性输血治疗可能对避免视网膜激光光凝或玻璃体切除术具有保护作用。
- 视觉症状如视物模糊或飞蚊症与SCR进展相关,可能作为转诊视网膜检查的指征。
研究设计与样本
- 回顾性队列研究,纳入296例同时就诊于镰状细胞病专科门诊和视网膜门诊的患者。
- 采用多因素多项逻辑回归评估各临床变量与SCR严重程度的关联。
主要发现
- 镰状细胞贫血基因型患者中,年龄较大(95%CI 1.04-1.15;P<.001)和男性(95%CI 0.13-0.87;P=.02)与增殖性镰状细胞视网膜病变相关。
- 基因变异型患者中,视觉症状(95%CI 1.36-21.62;P=.02)与增殖性镰状细胞视网膜病变相关。
- 全队列中,激光光凝和玻璃体切除术与年龄较大(95%CI 1.05-1.13;P<.001)、视觉症状(95%CI 1.48-7.40;P=.004)、较高血红蛋白水平(95%CI 1.14-1.65;P=.001)及未接受慢性输血(95%CI 0.16-1.09;P=.08)相关。
临床怎么用
- 视觉症状如视物模糊或飞蚊症可能提示SCR进展,可考虑转诊进行视网膜检查。
- 慢性输血治疗可能降低需视网膜激光光凝或玻璃体切除术的风险。
局限性
- 需要前瞻性研究进一步探讨SCR的危险因素并识别有发生或进展视网膜病变风险的镰状细胞病患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify associations between severity of sickle cell retinopathy (SCR) and other clinical, laboratory, or treatment factors relevant to sickle cell disease (SCD). DESIGN: Retrospective cohort study. METHODS: We investigated clinical, laboratory, and demographic associations with the severity of SCR in 296 patients seen at both our SCD specialty clinic and our retina clinic. Multivariate multinomial logistic regression was used to estimate the association between each clinical variable and severity of SCR. RESULTS: Multivariate analysis showed that in patients with sickle cell anemia (SCA) genotypes, older age (95% confidence interval [CI], 1.04-1.15; P < .001) and male sex (95% CI, 0.13-0.87; P = .02) were associated with proliferative sickle cell retinopathy (PSR). In patients with genotypic variants, visual symptoms (95% CI, 1.36-21.62; P = .02) were associated with PSR. Laser photocoagulation and vitrectomy surgery, the standard interventions for PSR, were associated with older age (95% CI, 1.05-1.13; P < .001), visual symptoms (95% CI, 1.48-7.40; P = .004), higher hemoglobin level (95% CI, 1.14-1.65; P = .001), and no chronic transfusion (95% CI, 0.16-1.09; P = .08) across the whole cohort. CONCLUSIONS: These findings may inform clinicians of the symptoms, systemic findings, and disease-modifying therapies most frequently associated with SCR in SCD patients. Visual symptoms such as blurred vision or floaters were associated with progression of SCR and may be criteria for referral for retinal examination. Chronic transfusion therapy may be protective against the need for retinal laser photocoagulation or vitrectomy. Prospective studies are necessary to further explore risk factors for SCR and to identify which individuals with SCD are at risk for incident or progression of retinopathy.
引用
- Duan XJ, Lanzkron S, Linz MO, et al. Clinical and Ophthalmic Factors Associated With the Severity of Sickle Cell Retinopathy. Am J Ophthalmol. 2018. PMID: 30278160. doi:10.1016/j.ajo.2018.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。